May 11, 2023 4:05 pm EDT Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
May 8, 2023 8:00 am EDT Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
Mar 30, 2023 4:05 pm EDT Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update